Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks

4. United Therapeutics Corporation (NASDAQ:UTHR)

Value of Renaissance Technologies’ 13F Position: $534 million

Number of Hedge Fund Shareholders: 46

Jim Simons’ quant fund trimmed the size of its United Therapeutics Corporation (NASDAQ:UTHR) stake by 9% during Q3, owning 2.55 million UTHR shares on September 30. Only one fund among the select group of money managers tracked by Insider Monkey’s database had a larger position in United Therapeutics than Renaissance Technologies, that being Behzad Aghazadeh’s VenBio Select Advisor, which owned 2.93 million shares and had 11.3% 13F exposure to the stock.

United Therapeutics Corporation (NASDAQ:UTHR) has a portfolio of drugs that focus on mitigating the effects of hypertension, particularly in those looking to exercise or perform other strenuous activities. Strong sales for hypertension treatment Tyvaso helped propel the company to 16% quarter-over-quarter sales growth in Q3, with overall sales hitting $516 million.

Analysts seem to be split on United Therapeutics Corporation (NASDAQ:UTHR)’s near-term potential. On the one hand, analysts’ consensus 2023 earnings estimates have jumped by nearly 50% to $2.83 in recent months. On the other hand, Goldman Sachs recently slapped a ‘Sell’ rating and $230 price target on the stock ($48 below its current price), citing a lack of growth drivers.